Condition: Major Depressive Disorder · Sponsor: Xenon Pharmaceuticals Inc.
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
This description comes directly from the study's public registry record.
Xenon Medical Affairs · 1-604-484-3300 · XenonCares@xenon-pharma.com
Always discuss trial participation with your own doctor first.
| IMA Clinical Research Phoenix | Phoenix, Arizona, United States | Recruiting |
| Woodland International Research Group | Little Rock, Arkansas, United States | Recruiting |
| Woodland Research Northwest | Rogers, Arkansas, United States | Recruiting |
| Behavioral Research Specialists, Llc | Glendale, California, United States | Recruiting |
| Marvel Clinical Research | Huntington Beach, California, United States | Recruiting |
| Irvine Clinical Research | Irvine, California, United States | Recruiting |
| CalNeuro Research Group, Inc. | Los Angeles, California, United States | Recruiting |
| Excell Research Inc. | Oceanside, California, United States | Recruiting |
| Atp Clinical Research | Orange, California, United States | Recruiting |
| Nrc Research Institute | Orange, California, United States | Recruiting |
| CenExel CNS-TO (Collaborative Neuroscience Research) | Torrance, California, United States | Recruiting |
| Sunwise Clinical Research | Walnut Creek, California, United States | Recruiting |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06775379